L. Wu, MD; C.P. Allaart, MD, PhD; G.J. de Roest, MD; M.L. Hendriks, MA; A.C. van Rossum, MD, PhD; C.C. de Cock MD, PhD ACC Scientific Sessions, San Francisco,

Slides:

Advertisements

Similar presentations

Presenter Disclosure Information

Advertisements

Ventricular Pressure-Volume Loops

EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.

Cardiac Resynchronization Therapy

CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies

Primary Results from the SMART AV DELAY Trial: A Randomized Trial Comparing Empiric, Echocardiographic Guided and Algorithmic AV Delay Programming in Cardiac.

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Se, come e quando l’ottimizzazione è necessaria? How and When Optimization Is Needed? M. Cristina Porciani Firenze.

Diminished Left Ventricular Dyssynchrony and Impact of Resynchronization in Failing Hearts With Right Versus Left Bundle Branch Block J Am Coll Cardiol.

Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.

Optimization of CRT via EKG Is simple better? Winter Arrhythmia School February 11, 2012 Irving Tiong, MD FRCPC Arrhythmia Service.

CRT-D Effectiveness by QRS Duration and Morphology in the MADIT-CRT Patients Wojciech Zareba, MD, PhD, Helmut Klein, MD, Iwona Cygankiewicz, MD, PhD, W.

Alon Barsheshet, MD1, Paul J. Wang, MD2, Arthur J. Moss, MD1, Scott D

Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.

Heart Failure Ben Starnes MD FACC Interventional Cardiology

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Quantitative Assessment of Congestive.

Treatment of Heart Failure: Beyond Medical Therapy

La selezione dei pazienti candidati alla Terapia Resincronizzante Cardiaca M Cristina Porciani Firenze “Incontri Pitagorici di Cardiologia 2010” “Πυθαγόρειοι.

Working Group of Heart Failure and Cardiac Function How to evaluate and treat dyssynchrony ? P Lancellotti, LA Piérard, Liège, BE.

Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:

Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.

Cardiac Resynchronization Therapy (CRT) Is an Effective Treatment for Heart Failure and Indications Are Expanding Multiple trials have shown the clinical.

New Application of Biventricular Pacing - Xiamen, 2010

Left Ventricular Twist Mechanics in Heart Failure: Evolving Role in the Assessment of Cardiac Dyssynchrony M Bertini, PP Sengupta, G Nucifora, V Delgado,

Dr Eric Prystowsky Director Clinical Electrophysiology Laboratory St Vincent Hospital, Indianapolis Dr Leslie Saxon Chief, Electrophysiology Laboratory.

An ICD for every CRT patient ?

Multi Point Pacing (MPP)

Complex Devices..... Biventricular Pacemaker: (aka Cardiac Resynchronisation Therapy) Treats subset of patients with heart failure Needs high quality.

CRT Overview This lecture is intended to give a basic overview of HF to include: -General knowledge of the cardiac cycle and how a normal heart should.

METHODS The EASYTRAK 2 lead was studied along with the CONTAK  RENEWAL  2/4/4HE device in the Device Evaluation of the CONTAK RENEWAL 2/4/4HE with EASYTRAK.

RCTs in Cardiac Resynchronization Therapy StudyPtNYHALVEFLVEDDRhythmQRSICD PATH-CHF41III,IV≤35%AnySR≥120N MUSTIC58III≤35%≥60SR≥150N MIRACLE453III,IV≤35%≥55SR≥130N.

Left Ventricular Pacing in the Early Post MI Period: Impact on LV Remodeling Eugene S.Chung, MD Director, Heart Failure Program, Director of Outcomes,

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.

Management of mitral regurgitation. See legend for Fig

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Diminished Left Ventricular Dyssynchrony and Impact of Resynchronization in Failing Hearts With Right Versus Left Bundle Branch Block J Am Coll Cardiol.

– р<0.05 between baseline

George E. Yanulis, MEng, MS, Pascal Lim, MD, Ali Ahmad, MD, Zoran B

Assessment of Intraventricular Mechanical Dyssynchrony and Prediction of Response to Cardiac Resynchronization Therapy: Comparison between Tissue Doppler.

The 28th Great Wall International Congress of Cardiology

Kuznetsov VA, Soldatova AM, Krinochkin DV, Enina TN

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Effect of Cardiac Resynchronization Therapy on Right.

Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing.

2) Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114

Optimal Pacing for Right Ventricular and Biventricular Devices

Left Ventricular and Biventricular Pacing in Congestive Heart Failure

Volume 12, Issue 7, Pages (July 2015)

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

Clyde W. Yancy et al. JACC 2017;70:

Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)

Clyde W. Yancy et al. JACC 2017;70:

David D. Berg et al. JACC 2018;71:

George E. Yanulis, MEng, MS, Pascal Lim, MD, Ali Ahmad, MD, Zoran B

Angelo Auricchio, and Frits W. Prinzen JACEP 2017;3:

Mintu P. Turakhia et al. JACEP 2016;2:

Ethnic and racial disparities in cardiac resynchronization therapy

Volume 14, Issue 12, Pages (December 2017)

Angelo Auricchio, and Frits W. Prinzen JACEP 2017;j.jacep

Understanding the cardiac substrate and the underlying physiology: Implications for individualized treatment algorithm John Gorcsan, MD, Frits W. Prinzen,

Emilce Trucco et al. JACEP 2018;j.jacep

Intentional anodal capture of a left ventricular quadripolar lead enhances resynchronization equally with multipoint pacing Itsuro Morishima, MD, PhD,

Isolated right ventricular failure and abnormal hemodynamics caused by right ventricular pacing are reversed with cardiac resynchronization therapy Milena.

Rick A. Nishimura et al. JACC 2017;70:

Volume 16, Issue 7, Pages (July 2019)

Presentation transcript:

L. Wu, MD; C.P. Allaart, MD, PhD; G.J. de Roest, MD; M.L. Hendriks, MA; A.C. van Rossum, MD, PhD; C.C. de Cock MD, PhD ACC Scientific Sessions, San Francisco, CA 9 March 2013 The influence of right ventricular pacing on response to biventricular stimulation -An acute pressure-volume loop study-

Cardiac resynchronization therapy Standard therapy in end-stage heart failure LV only versus biventricular pacing Leclercq et al. JACC 2002Thibault et al., Circ 2011Kass et al., Circ 1999 p=0.001

Cardiac resynchronization therapy Contribution RV only pacing? –Detrimental effects on LV –In LBBB patients –Higher degree of mechanical dyssynchrony –Decrease in contractility Thambo et al., Circ 2004Sweeney et al., JACC 2006Auricchio et al., JACC 2002Tops et al., JACC 2009

Aim To investigate the influence of RV pacing on hemodynamic response during biventricular stimulation

Methods Patients eligible for CRT –Temporary pacing leads –Conductance measurements RA lead RV lead PL lead Conductance catheter

Pressure-volume loop Baseline RV only LV only Biventricular

Results Baseline characteristicsn=59 Age (yrs)67±10 Male39 (66%) QRS (ms)154±21 Ischaemic, n36 (61%) NYHA, n I / II / III / IV0 / 14 / 45 / 0 NT-pro BNP (ng/L)1637±1375 LVEDV (ml)294±151 LVESV (ml)232±142 LVEF (%)22±13

Acute effect of pacing on SW p=NS p<0.001 p=NS

Acute effect of pacing on dP/dt max p<0.001 p=NS p=0.002 p=NS

Correlation RV only and Biv response LV only gives a larger SW improvement than Biv Biv gives a larger SW improvement than LV only ∆ SW Biv - ∆ SW LV only (%)

Clinical consequences Response > 20% SW increase de Roest et al., Eur J HF 2012 Responders 68%

Non-responders SW improvement < 20% 52% better SW response 34% responders BivLV only

Conclusion Acute SW change during CRT is significantly modulated by RV pacing The amount of modulation is similar to the SW response during RV pacing Addition of RV pacing to LV pacing may positively or negatively affect outcome In CRT non-responders, the effect of switching off RV pacing should be evaluated individually

Acknowledgement VU University Medical Center Amsterdam –C.P. Allaart, MD, PhD –G.J. de Roest, MD –M.T. Rijnierse, MD –M.L. Hendriks, MA –A.C. van Rossum, MD, PhD –C.C. de Cock, MD, PhD Thank you!

SW response to Biv pacing Responders (n=30)Non-responders (n=29)p-value Age (yrs)67±1167± Male14 (47%)25 (86%)<0.01 QRS (ms)154±17154± Ischemic, n17 (57%)19 (66%)0.49 NYHA, n I / II / III / IV0 / 6 / 20 / 10 / 8 / 21 / NT-pro BNP (ng/L)1440± ± LVEDV (ml)225±89335± LVESV (ml)187±62279± LVEF (%)26±919±

SW response to LV pacing 16 Responders (n=40)Non-responders (n=19)p-value Age (yrs)67±1168±90.83 Male25 (63%)14 (74%)0.40 QRS (ms)155±20152± Ischemic, n22 (55%)14 (74%)0.17 NYHA, n I / II / III / IV0 / 29 / 1 / 00 / 4 / 15 / NT-pro BNP (ng/L)1649± ± LVEDV (ml)267±92351± LVESV (ml)202±77297± LVEF (%)25±1017±170.03

Non-response Reverse response > 20% SW decrease 17 Reverse responders 21%

Correlation dP/dt max 18 ∆ SW Biv - ∆ SW LV only (%) LV only gives a larger SW improvement than Biv Biv gives a larger SW improvement than LV only ∆SW RV (%)